{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:56:13Z","timestamp":1791053773255,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.jaad.2006.06.038","type":"journal-article","created":{"date-parts":[[2006,9,9]],"date-time":"2006-09-09T07:17:27Z","timestamp":1157786247000},"page":"807-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides"],"prefix":"10.1016","volume":"55","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristilyn","family":"Zonno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.06.038_bib1","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/1521-4141(200107)31:7<2227::AID-IMMU2227>3.0.CO;2-C","article-title":"Early Th1\/Th2 cell polarization in the absence of IL-4 and IL-12: T cell receptor signaling regulates the response to cytokines in CD4 and CD8 T cells","volume":"31","author":"Noble","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0962-8924(00)01856-0","article-title":"The molecular basis of T helper 1 and T helper 2 cell differentiation","volume":"10","author":"O'Garra","year":"2000","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.jaad.2006.06.038_bib3","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.158.6.2654","article-title":"Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals","volume":"158","author":"Palmer","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/1521-4141(200104)31:4<1055::AID-IMMU1055>3.0.CO;2-7","article-title":"IL-12-induced reversal of human Th2 cells is accompanied by full restoration of IL-12 responsiveness and loss of GATA-3 expression","volume":"31","author":"Smits","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.184.2.473","article-title":"Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level","volume":"184","author":"Sornasse","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2006.06.038_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00812257","article-title":"Th1\/Th2 subsets: distinct differences in homing and chemokine receptor expression?","volume":"21","author":"Syrbe","year":"1999","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.jaad.2006.06.038_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/08830189809043002","article-title":"Pro-inflammatory and immunoregulatory functions of interleukin-12","volume":"16","author":"Trinchieri","year":"1998","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1006\/cimm.2001.1850","article-title":"Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype","volume":"212","author":"Wesch","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib9","first-page":"16","article-title":"Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis","volume":"107","author":"Rook","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib10","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.163.7.4073","article-title":"Depressed IL-12-mediated signal transduction in T cells from patients with S\u00e9zary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4","volume":"163","author":"Showe","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/hupa.2002.32215","article-title":"CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas","volume":"33","author":"Dorfman","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jaad.2006.06.038_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2003.132","article-title":"Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides","volume":"48","author":"Kakinuma","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2002-02-0475","article-title":"Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma","volume":"101","author":"Kleinhans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2006.06.038_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/1523-1747.ep12330869","article-title":"Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA","volume":"107","author":"Asadullah","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.154.3.1491","article-title":"IL-12 reverses cytokine and immune abnormalities in S\u00e9zary syndrome","volume":"154","author":"Rook","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","article-title":"Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma","volume":"103","author":"Vowels","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T\u00a0cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2006.06.038_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1521-4141(200001)30:1<204::AID-IMMU204>3.0.CO;2-G","article-title":"Macrophage-derived chemokine production by\u00a0activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines","volume":"30","author":"Galli","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2006.06.038_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1523-1747.2000.00995.x","article-title":"Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis","volume":"115","author":"Echchakir","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00007454","article-title":"T-cell clones from early-stage cutaneous T-cell lymphoma show no polarized Th-1 or Th-2 cytokine profile","volume":"292","author":"Harwix","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2006.06.038_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0733-8635(05)70312-0","article-title":"Cutaneous T-cell lymphoma. New immunomodulators","volume":"19","author":"Apisarnthanarax","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2006.06.038_bib23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2006.06.038_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2006.06.038_bib25","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/archderm.135.10.1204","article-title":"Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept","volume":"135","author":"Schmid","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.138.1.42","article-title":"Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT)","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.038_bib27","first-page":"2682","article-title":"Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?","volume":"7","author":"Ni","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.06.038_bib28","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.06.038_bib29","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12\u00a0in patients with metastatic renal cell cancer or malignant\u00a0melanoma: ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.06.038_bib30","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.06.038_bib31","first-page":"9","article-title":"Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer","volume":"5","author":"Robertson","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.06.038_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002371-200307000-00006","article-title":"Phase I study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder","volume":"26","author":"Weiss","year":"2003","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jaad.2006.06.038_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-002-0356-5","article-title":"IL-12: a promising adjuvant for cancer vaccination","volume":"52","author":"Portielje","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaad.2006.06.038_bib34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2003.12.144","article-title":"Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell\u00a0responses in advanced melanoma","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220601872X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220601872X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:04:25Z","timestamp":1759269865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096220601872X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S019096220601872X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.06.038","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}